Mimetas, a leader in organ-on-chip-based disease models and technology, and Roche, a leading pharmaceutical company, have entered into a collaboration to develop human disease models to characterize novel compounds in inflammatory bowel disease (IBD) and hepatitis B virus infections (HBV). Under the terms of the agreement, Mimetas is eligible to receive an upfront payment and milestone payments from Roche.   Mimetas will be responsible for developing tissue-based disease models and assays in t...